An observational study in Erectile Dysfunction, Depression and Perception and Beliefs, sponsored by Haseki Training and Research Hospital. Enrolling by invitation at 1 site in Turkey (Türkiye). Open to male participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2025-08-12.
Sponsored by Haseki Training and Research Hospital · Observational
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 32 studies in Erectile Dysfunction with a site in Turkey — 6 open to participants now, 8 under way, 2 of them phase 3. Erectile Dysfunction · Turkey.
Among the 32 studies in Erectile Dysfunction with a site in Turkey, this one is the 9th largest by planned enrollment of the 15 observational ones that give a count, is one of 6 that started in 2025, is one of 15 observational ones, and was the 19th registered.
702 studies on the registry are indexed under Erectile Dysfunction; 125 are open to participants now.
Browse Erectile Dysfunction studies →6 of the 32 studies in Erectile Dysfunction with a site in Turkey are open now. Recruiting first, the newest first:
Uskudar University · Sites in Turkey
Ages 25–45 · Men only · Healthy volunteers
Ankara City Hospital Bilkent · Sites in Turkey
Ages 25–75 · Men only
Varol TUNALI · Sites in Turkey
Ages 30–65 · Men only
Medipol University · Sites in Turkey
Ages 45–75 · Men only
Hacettepe University · Sites in Turkey
Ages 40+ · Men only
A study can be open while its sites in Turkey have not opened yet or have stopped. Only those recruiting at a site in Turkey →
Of the 78 Erectile Dysfunction studies recruiting now, 31 (40%) set no upper age limit and 34 (44%) stop at 75 or younger; 2 take children under 18; 7 take healthy volunteers.
This study: 18 Years and older · male · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
32 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 2 1 · Phase 3 3 · Phase 4 5
First in 2002; this study’s year is marked. 6 started in 2025.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 120 is close to the median of 133 across 126 observational studies indexed under Erectile Dysfunction.
Median enrollment 60 across the 17 interventional studies, 130 across the 15 observational. Of the 20 that completed or were terminated, 0 (0%) have results posted.
This tab as a report to print or save as PDF → With an account.
7 of 32 have an industry lead sponsor. The 10 most frequent:
Haseki Training and Research Hospital is the lead sponsor of 78 studies on the registry; 17 are open to participants now.
Haseki Training and Research Hospital has 1 study filed under Erectile Dysfunction — fewer than ten, so there is no comparison to draw.
2 of the studies in Erectile Dysfunction with a site in Turkey that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07707505Medipol UniversityIntracavernosal Exosomes vs. Rectal Ozone for Post-RARP Erectile Dysfunction | 2027-01-01 |
| NCT07761546Varol TUNALIAIM-TEST: Microbiome-Targeted Nutrition for Functional Secondary Hypogonadism | 2027-04-30 |
Add all 2 to your calendar (.ics) → With an account.
Among the 32 studies in Erectile Dysfunction with a site in Turkey, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The goal of this observational study is to evaluate the impact of illness perception and depressive symptoms on treatment outcomes in adult male patients diagnosed with erectile dysfunction (ED).
The main questions it aims to answer are:
Is there a relationship between negative illness perception and increased severity of depressive symptoms in ED patients? Does the change in illness perception over time correlate with changes in erectile function and depression levels?
Participants will:
Complete the IIEF-5 (International Index of Erectile Function - 5) to assess erectile dysfunction severity, Complete the B-IPQ (Brief Illness Perception Questionnaire) to evaluate their cognitive and emotional representations of ED, Complete the PHQ-9 (Patient Health Questionnaire - 9) to measure depressive symptoms, Repeat these assessments at baseline and at a 1-month follow-up. This study does not involve any intervention or comparison group. It is designed to track psychological and clinical changes over time and explore modifiable psychological predictors in the management of ED.
This prospective, observational study aims to investigate the relationship between illness perception and depressive symptoms in patients diagnosed with erectile dysfunction (ED), and how these factors influence treatment response over time. Erectile dysfunction is a multifactorial condition that significantly affects quality of life and can be shaped by psychological and cognitive factors, including patients' perceptions of their disease.
A total of 120 adult male participants (aged >18 years) diagnosed with ED will be enrolled from multiple urology centers. Patients will complete three validated instruments at baseline and again at a 1-month follow-up:
IIEF-5 (International Index of Erectile Function - 5): to assess severity of erectile dysfunction.
B-IPQ (Brief Illness Perception Questionnaire): to evaluate cognitive and emotional representations of their condition.
PHQ-9 (Patient Health Questionnaire - 9): to screen for and quantify depressive symptoms.
The primary outcome of the study is to determine the association between baseline illness perception (as measured by B-IPQ) and the severity of depressive symptoms (PHQ-9 scores). Secondary outcomes include changes in erectile function (IIEF-5) and depressive symptoms at 1 month, and whether these changes correlate with changes in illness perception. Additionally, specific components of illness perception such as personal control, treatment control, concern, and emotional response will be analyzed in relation to treatment adherence and psychological well-being.
Data Quality and Management Procedures:
A structured case report form (CRF) will be used for consistent data entry. A data dictionary will define each variable and ensure uniform interpretation of collected data.
Data checks will be performed to validate internal consistency (e.g., checking for missing or out-of-range values).
Source data verification will involve comparison of collected responses with patients' medical records when applicable.
Standard Operating Procedures (SOPs) will be followed for data collection, participant follow-up, and data management.
Sample Size and Statistical Plan:
A power analysis indicated a required sample size of 120 participants to detect a moderate correlation (r = 0.3) between illness perception and depressive symptoms with 80% power and a 5% significance level.
Statistical analysis will include:
Descriptive statistics for demographic and clinical variables. Pearson or Spearman correlation analysis between B-IPQ, PHQ-9, and IIEF-5 scores.
Paired t-tests or Wilcoxon signed-rank tests to assess within-group changes over time.
Multivariate regression analysis to control for potential confounders such as age, comorbidities, and duration of ED.
Missing Data Plan:
Cases with missing responses will be addressed using multiple imputation methods where appropriate. Sensitivity analyses will be conducted to assess the impact of missing data on study outcomes.
This study will provide insight into how modifiable psychological factors such as illness beliefs influence both psychological distress and sexual health, potentially informing future patient education and intervention strategies.
Participants will be recruited from the outpatient urology clinics of Haseki Training and Research Hospital and collaborating centers. All participants will be adult male patients who present with complaints consistent with erectile dysfunction and meet the diagnostic criteria during clinical evaluation.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
This study includes adult male participants aged 18 and older who have been clinically diagnosed with erectile dysfunction (ED). All participants will have the condition of interest (ED), and there is no control group without the condition. The study group is homogeneous in that it consists solely of patients with ED, allowing for the evaluation of intra-individual changes over time in illness perception, depressive symptoms, and erectile functio
Association between illness perception and depressive symptoms
Change in depressive symptom scores (Patient Health Questionnaire-9, PHQ-9; range 0-27; higher scores indicate worse depressive symptoms) in relation to illness perception scores (Brief Illness Perception Questionnaire, B-IPQ; range 0-80; higher scores indicate more negative illness perceptions) at baseline and 1-month follow-up.
Time frame: Baseline and 1-month follow-up
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: Yes — Individual participant data (IPD) will be made available to qualified researchers upon reasonable request. Requests will be evaluated by the principal investigator to ensure that the proposed use is scientifically and ethically appropriate. Data will be shared under a formal data use agreement that protects participant confidentiality and complies with ethical standards.
Supporting information: Study protocol, Informed consent form
Time frame: Data will be available starting 6 months after publication of the study results and will remain available for up to 2 years.
Access criteria: Qualified researchers affiliated with academic institutions, research organizations, or healthcare institutions may request access to the data. What information they can access: Individual participant data (IPD) Study protocol Statistical analysis plan Informed consent form (upon request) How they can access it: Researchers must submit a formal request to the principal investigator including a brief research proposal and institutional ethical approval. If the request is approved, a data use agreement (DUA) must be signed to ensure appropriate data handling and confidentiality. Access will then be granted through a secure, password-protected electronic transfer system managed by the study team.
Data sharing details ↗ · vivli.org
Started Mar 2025 (actual). Primary completion is estimated for Aug 2025, 5 months after the start.
Of 41 observational studies under Erectile Dysfunction, half reached primary completion within 36 months of starting (the median), counting those still running; a quarter within 11 and three quarters within 77. This study's planned 5 months is below that.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
No contact was published for this record. The registry link below has the sponsor’s details.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Haseki Training and Research Hospital